{"id":33854,"date":"2025-10-31T18:05:39","date_gmt":"2025-10-31T12:35:39","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33854"},"modified":"2025-11-03T18:03:55","modified_gmt":"2025-11-03T12:33:55","slug":"novo-metsera-acquisition","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition","title":{"rendered":"Pharma Rivalry Intensifies: Novo Nordisk Looks to Wrest Metsera from Pfizer"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f5973eaaa78\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f5973eaaa78\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition\/#The_Bidding_War_Intensifies\" >The Bidding War Intensifies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition\/#The_Prize_Metseras_Promising_Obesity_Pipeline\" >The Prize: Metsera\u2019s Promising Obesity Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition\/#Market_Implications_and_Industry_Outlook\" >Market Implications and Industry Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition\/#Pfizers_Troubled_Obesity_Journey\" >Pfizer\u2019s Troubled Obesity Journey<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition\/#A_Defining_Moment_for_the_Obesity_Drug_Race\" >A Defining Moment for the Obesity Drug Race<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>In an unprecedented move that has sent shockwaves through the pharmaceutical industry, Danish drugmaker <strong>Novo Nordisk<\/strong> launched an unsolicited<strong> ~$9 billion<\/strong> bid to acquire obesity-focused biotech <strong>Metsera<\/strong>, directly challenging a deal <strong>Pfizer <\/strong>had already secured. The aggressive counteroffer, announced on October 30, 2025, marks a dramatic escalation in the race to dominate the rapidly expanding <a href=\"https:\/\/www.delveinsight.com\/blog\/transforming-obesity-treatment\">weight-loss drug market<\/a> and signals a strategic shift for Novo Nordisk under new leadership.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-bidding-war-intensifies\"><span class=\"ez-toc-section\" id=\"The_Bidding_War_Intensifies\"><\/span><strong>The Bidding War Intensifies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer and Novo Nordisk are engaged in a high-profile legal battle over the acquisition of Metsera, a clinical-stage biotech focused on obesity treatments. Pfizer initially agreed to acquire Metsera for <strong>$4.9 billion<\/strong> plus up to <strong>$2.4 billion<\/strong> in milestones, totaling a potential <strong>$7.3 billion<\/strong>. However, Novo Nordisk made a counteroffer valuing Metsera at up to <strong>$9 billion<\/strong>, surpassing Pfizer\u2019s offer and prompting a fierce response from Pfizer.<\/p>\n\n\n\n<p>Pfizer has filed a lawsuit in the Delaware Court of Chancery against Metsera, its board of directors, and Novo Nordisk, accusing them of breach of contract, breach of fiduciary duty, and tortious interference in contract. Pfizer argues that Novo Nordisk\u2019s bid cannot be considered a \u201cSuperior Company Proposal\u201d under the merger agreement because of its high regulatory risk and an \u201cunprecedented structure\u201d designed to evade antitrust review. Pfizer also claims that Novo\u2019s proposal constitutes an illegal attempt by a dominant market player to suppress competition.<\/p>\n\n\n\n<p>Supporting its position, Pfizer secured early antitrust clearance from the U.S. Federal Trade Commission (FTC) for its acquisition of Metsera, allowing Pfizer to potentially close the deal shortly after Metsera\u2019s shareholder meeting scheduled for <strong>November 13, 2025<\/strong>. Pfizer has requested a temporary restraining order to block Metsera from terminating the agreement with Pfizer while the legal case unfolds.<\/p>\n\n\n\n<p>The conflict is a landmark clash between two pharma giants in the rapidly expanding obesity treatment market, with Pfizer accusing Novo Nordisk of reckless tactics and Novo Nordisk asserting that its offer is superior. The lawsuit and acquisition race mark a critical juncture in obesity drug development competition, with significant implications for all parties involved and the broader market landscape. This legal dispute underscores the complexities of M&amp;A in biotech, particularly when regulatory risk, market dominance, and competitive positioning intersect in high-stakes deals.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-prize-metsera-s-promising-obesity-pipeline\"><span class=\"ez-toc-section\" id=\"The_Prize_Metseras_Promising_Obesity_Pipeline\"><\/span><strong>The Prize: Metsera\u2019s Promising Obesity Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>At the heart of this corporate showdown is Metsera\u2019s innovative portfolio of obesity treatments, particularly its lead candidate <strong>MET-097i<\/strong>, a first-in-class, ultra-long-acting <a href=\"https:\/\/www.delveinsight.com\/report-store\/glucagon-like-peptide1-glp1-agonists-market-forecast\">GLP-1 receptor agonist<\/a> designed for potentially monthly dosing. This represents a significant advancement over current market leaders, such as Novo\u2019s WEGOVY and Eli Lilly\u2019s ZEPBOUND, which require weekly injections.<\/p>\n\n\n\n<p>Recent Phase IIb trial results have demonstrated MET-097i\u2019s impressive profile. In the <strong>VESPER-1 study<\/strong>, the drug achieved a mean placebo-subtracted weight loss of 14.1% after 28 weeks at the highest dose (1.2 mg), with some individuals losing as much as 26.5% of their body weight. Exploratory analysis of 36-week data revealed substantial continued weight loss, with no plateau reached, suggesting that the drug&#8217;s full effects extend beyond the initial trial period.<\/p>\n\n\n\n<p>Equally compelling is <a href=\"https:\/\/www.delveinsight.com\/blog\/metseras-glp-1-receptor-agonist-met-097i\">MET-097i\u2019s tolerability profile<\/a>. In the <strong>VESPER-3 trial<\/strong> evaluating monthly dosing regimens, participants who titrated to the highest dose of 1.2 mg experienced minimal diarrhea, with only a 13% increase in nausea and an 11% increase in vomiting compared to placebo, substantially lower rates than those seen with competing GLP-1 drugs. Only 2.9% of participants (two out of 239) discontinued treatment due to adverse events in the VESPER-1 study, compared to discontinuation rates of up to 10% for other obesity medications.<\/p>\n\n\n\n<p>The drug\u2019s potency is remarkable, requiring 5-10 times lower doses than current GLP-1 options while achieving comparable efficacy to tirzepatide, the active ingredient in Eli Lilly\u2019s ZEPBOUND. This translates to significant manufacturing and scalability advantages in a market currently constrained by supply limitations.<\/p>\n\n\n\n<p>Based on these positive results, Metsera is on track to initiate <strong>Phase III trials in late 2025<\/strong>, with potential FDA approval projected for 2027 or 2028. Beyond MET-097i as a monotherapy, Metsera\u2019s pipeline includes <strong>MET-233<\/strong>. This ultra-long-acting amylin analog could be combined with MET-097i as a first-in-category monthly multi-hormone therapy, as well as MET-815, an oral prodrug of MET-097i.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications-and-industry-outlook\"><span class=\"ez-toc-section\" id=\"Market_Implications_and_Industry_Outlook\"><\/span><strong>Market Implications and Industry Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Metsera bidding war reflects broader trends in pharmaceutical M&amp;A, particularly in the obesity and cardiometabolic space. Novo Nordisk has dominated obesity-focused dealmaking, signing <strong>17 obesity-focused deals<\/strong> between 2020 and Q1 2025, while Eli Lilly announced <strong>seven deals<\/strong> during the same period. Obesity partnering deal volume doubled in 2024 to 36 agreements, up from 18 in 2023, with licensing deals experiencing the most significant jump.<\/p>\n\n\n\n<p>However, merger and acquisition activity specifically in the obesity sector showed a \u201cyo-yo effect,\u201d with deal volume declining from <strong>$7.5 billion<\/strong> across 21 deals in 2023 to <strong>$1.4 billion<\/strong> across 20 deals in 2024. This slowdown reflected acquirers waiting for next-generation medicines to be sufficiently de-risked before committing significant capital.<\/p>\n\n\n\n<p>The Metsera competition signals that this cautious period may be coming to an end. Companies like <strong>Viking Therapeutics, Altimmune, and Structure Therapeutics<\/strong>, all developing <a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-drugs-launch\">weight-loss drugs<\/a> in clinical testing, saw their shares rise following the announcement.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pfizer-s-troubled-obesity-journey\"><span class=\"ez-toc-section\" id=\"Pfizers_Troubled_Obesity_Journey\"><\/span><strong>Pfizer\u2019s Troubled Obesity Journey<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>For Pfizer, the loss of Metsera would represent a significant setback in its renewed effort to re-enter the <a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\">obesity market<\/a> after a series of clinical disappointments. The company had already terminated two oral GLP-1 programs due to safety concerns: <strong>Lotiglipron <\/strong>was discontinued in late 2023 after elevated liver enzymes were detected in clinical trials, and <strong>Danuglipron <\/strong>was abandoned in April 2025 following a suspected case of drug-induced liver injury in a Phase I participant. Pfizer\u2019s third and final in-house GLP-1 agonist, <strong>PF-06954522<\/strong>, was discontinued in August 2025, though not for safety-related reasons. These repeated failures left Pfizer without a viable obesity candidate in its internal pipeline, aside from early-stage collaborations with other companies. The acquisition of Metsera therefore represented Pfizer\u2019s best opportunity to quickly re-establish a competitive position in this rapidly expanding market. Losing Metsera to Novo would effectively send Pfizer back to square one, forcing it to pursue more costly alternatives or accept a diminished role in the obesity space.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-defining-moment-for-the-obesity-drug-race\"><span class=\"ez-toc-section\" id=\"A_Defining_Moment_for_the_Obesity_Drug_Race\"><\/span><strong>A Defining Moment for the Obesity Drug Race<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The obesity drug market is largely a battle of <a href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\">Novo Nordisk vs Eli Lilly<\/a>, and this deal has strengthened Novo\u2019s position. The fierce competition for Metsera reflects the extraordinary growth trajectory of the obesity drug market. The anti-obesity medication market, valued at approximately <strong>$12 billion<\/strong> in 2024 across the leading markets (the US, EU4, the UK, and Japan), is projected to reach between <strong>$88 billion<\/strong> by 2034, representing a compound annual growth rate of <strong>20.6%<\/strong>.<\/p>\n\n\n\n<p>The runaway success of GLP-1 therapies drives this explosive growth. Novo Nordisk\u2019s OZEMPIC and WEGOVY, along with Eli Lilly\u2019s MOUNJARO and ZEPBOUND, have collectively generated <strong>$71 billion<\/strong> in US revenue since 2018, with OZEMPIC alone accounting for approximately half of that total. With the market projected to become \u201cthe largest drug class,\u201d reaching up to <strong>222 million<\/strong> patients across the leading markets by 2034, access to next-generation therapies like Metsera\u2019s pipeline could determine competitive positioning for decades to come.\u200b<\/p>\n\n\n\n<p>The outcome will have far-reaching implications beyond the immediate financial terms. If Novo succeeds in acquiring Metsera despite antitrust concerns, it could embolden other market leaders to pursue aggressive consolidation strategies. Conversely, if regulatory scrutiny or legal challenges derail Novo\u2019s bid, it may establish precedents limiting how dominant players can expand their obesity portfolios through M&amp;A.<\/p>\n\n\n\n<p>The pharmaceutical industry is closely observing whether this high-stakes corporate clash will redefine competition in the <a href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-obesity-treatment\">obesity drug market<\/a> \u2014 and whether the advantages of monthly dosing, better tolerability, and groundbreaking weight loss will be claimed by the Danish pioneer of the GLP-1 revolution or the American contender striving for a comeback after multiple setbacks.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1024x194.png\" alt=\"Obesity-Market-Outlook-and-Assessment\" class=\"wp-image-28507\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>In an unprecedented move that has sent shockwaves through the pharmaceutical industry, Danish drugmaker Novo Nordisk launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer had already secured. The aggressive counteroffer, announced on October 30, 2025, marks a dramatic escalation in the race to dominate the rapidly expanding [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":33856,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20480,22409,22751,877,1173,19429,20479,18881,19430,460],"industry":[17225],"therapeutic_areas":[18720],"class_list":["post-33854","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-drugs-for-obesity","tag-glp-1-receptor","tag-metsera","tag-novo-nordisk","tag-obesity","tag-obesity-companies","tag-obesity-drugs","tag-obesity-market","tag-obesity-treatment","tag-pfizer","industry-pharmaceutical","therapeutic_areas-nutritional-disorders-and-weight-loss"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Moves to Secure Metsera, Threatening Pfizer\u2019s Hold<\/title>\n<meta name=\"description\" content=\"Danish drugmaker Novo launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Moves to Secure Metsera, Threatening Pfizer\u2019s Hold\" \/>\n<meta property=\"og:description\" content=\"Danish drugmaker Novo launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T12:35:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-03T12:33:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/31180259\/novo-metsera-acquisition.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Moves to Secure Metsera, Threatening Pfizer\u2019s Hold","description":"Danish drugmaker Novo launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition","og_locale":"en_US","og_type":"article","og_title":"Novo Moves to Secure Metsera, Threatening Pfizer\u2019s Hold","og_description":"Danish drugmaker Novo launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer.","og_url":"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-10-31T12:35:39+00:00","article_modified_time":"2025-11-03T12:33:55+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/31180259\/novo-metsera-acquisition.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition","url":"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition","name":"Novo Moves to Secure Metsera, Threatening Pfizer\u2019s Hold","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/31180259\/novo-metsera-acquisition.webp","datePublished":"2025-10-31T12:35:39+00:00","dateModified":"2025-11-03T12:33:55+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Danish drugmaker Novo launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/novo-metsera-acquisition#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/31180259\/novo-metsera-acquisition.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/31180259\/novo-metsera-acquisition.webp","width":466,"height":284,"caption":"novo-metsera-acquisition"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/31180259\/novo-metsera-acquisition-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">drugs for obesity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GLP-1 receptor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Metsera<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Obesity Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">drugs for obesity<\/span>","<span class=\"advgb-post-tax-term\">GLP-1 receptor<\/span>","<span class=\"advgb-post-tax-term\">Metsera<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">obesity<\/span>","<span class=\"advgb-post-tax-term\">obesity companies<\/span>","<span class=\"advgb-post-tax-term\">obesity drugs<\/span>","<span class=\"advgb-post-tax-term\">Obesity Market<\/span>","<span class=\"advgb-post-tax-term\">obesity treatment<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 months ago","modified":"Updated 6 months ago"},"absolute_dates":{"created":"Posted on Oct 31, 2025","modified":"Updated on Nov 3, 2025"},"absolute_dates_time":{"created":"Posted on Oct 31, 2025 6:05 pm","modified":"Updated on Nov 3, 2025 6:03 pm"},"featured_img_caption":"novo-metsera-acquisition","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33854"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33854\/revisions"}],"predecessor-version":[{"id":33861,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33854\/revisions\/33861"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33856"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33854"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33854"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}